Hepatic graft-versus-host disease (GVHD) generally presents as cholestatic jaundice, and increased serum alkaline phosphatase (ALP) is followed by hyperbilirubinemia and clinical jaundice. Currently accepted standards for evaluating the clinical severity of GVHD are based not on serum aminotransferase levels but on the serum bilirubin level. We describe a 17-year-old Japanese female who had increased aminotransferases without cholestasis on day 23 after allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Liver biopsy revealed lymphocytic infiltration of the portal tracts and pericentral necrosis of the lobuli. The limiting plates were not clearly defined due to cellular infiltrates. There was periductal lymphocytic infiltration and vacuolization of the biliary epithelial cells with exocytosis, compatible with GVHD of cholangiohepatitic type. These findings indicate that acute hepatic GVHD may present as acute hepatitis and this should be included in the differential diagnosis for patients with increased aminotransferases after allogeneic stem cell transplantation. Bone Marrow Transplantation (2001) 27, 1007-1010.
Liver dysfunction is a common complication after allogeneic hematopoietic stem cell transplantation, and the clinical features are frequently complicated by the concurrent effects of pretransplant chemoradiotherapy, graft-versus-host disease (GVHD), GVHD prophylaxis and viral infection on the liver. 1, 2 The hepatic manifestation of acute GVHD is characterized by cholestatic jaundice. In acute GVHD, an increased serum alkaline phosphatase (ALP) is usually followed by hyperbilirubinemia and mild hepatomegaly. On the other hand, elevation of serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) is usually delayed and mild. 3, 4 We describe a case of allogeneic peripheral blood stem cell transplantation (allo-PBSCT), complicated by marked elevation of the AST and ALT without significant elevation of the biliary tract enzymes on day 23 post transplant, clinically considered to be acute hepatitis but histologically diagnosed as hepatic GVHD.
Case report
A 17-year-old Japanese girl with acute myelomonocytic leukemia and trilineage myelodysplasia (AML/t-MDS) was admitted in May 1998. She received induction chemotherapy consisting of idarubicin (12 mg/m 2 /day i.v. on days 1-3) and cytarabine (Ara-C) (100 mg/m 2 i.v. on days 1-7) without obvious liver problems, but complete remission (CR) was not achieved. During the re-induction with mitoxantrone (7 mg/m 2 /day i.v. days [3] [4] [5] and Ara-C (500 mg/m 2 i.v. twice daily on days 1-7), serum levels of AST and ALT transiently increased up to 119 IU/l (normal Ͻ32 IU/l) and 304 IU/l (normal Ͻ39 IU/l), respectively, possibly because of antibiotic therapy for severe pneumonitis, after which CR was achieved. She received one course of consolidation chemotherapy with VP-16 (100 mg/m 2 /day i.v. days [1] [2] [3] [4] [5] and Ara-C (500 mg/m 2 i.v. twice daily on days 1-6) with no liver enzyme abnormalities.
She received allo-PBSCT from her HLA-identical sister during first complete remission, in October 1998. Before allo-PBSCT, her liver function tests including aminotransferases and biliary enzymes were within the normal ranges.
Serology tests for hepatitis A, B and C viruses were negative. For mobilization of peripheral blood stem cells (PBSCs), granulocyte colony-stimulating factor (G-CSF) (Filgrastim; Sankyo/Kirin, Tokyo, Japan) was administered subcutaneously to the donor at a dose of 10 g/kg for 5 days, as previously described. 5 PBSCs were collected by apheresis on days 4 and 5 of G-CSF administration in a continuous flow blood cell separator. The patient received a pretransplant conditioning regimen consisting of busulphan (4 mg/kg × 4 days) and cyclophosphamide (60 mg/kg × 2 days). Unmanipulated PBSCs containing 9. /l on day 9, and the platelets Ͼ50 × 10 9 /l on day 14. Figure 1 shows the clinical course. Although liver dysfunction was not observed before transplantation, her liver enzyme levels started to rise on day 1. On day 5, serum levels of AST and ALT had increased up to 100 IU/l (normal Ͻ32 IU/l) and 209 IU/l (normal Ͻ39 IU/l), respectively. Serum levels of bilirubin, ALP and ␥-GTP remained normal. AST and ALT returned to near normal levels by day 21 without any treatment. On day 23, her aminotransferase levels increased again to AST 204 IU/l and ALT 531 IU/l. While the bilirubin concentration remained normal (0.80 mg/dl) the ALP and ␥-GTP levels were mildly elevated: ALP 193 IU/l (normal Ͻ127 IU/l) and ␥-GTP 120 IU/l (normal Ͻ40 IU/l). She was afebrile, with no right upper quadrant abdominal pain or tenderness, and no significant weight gain, hepatomegaly, or ascites. Cutaneous and gastrointestinal manifestations of acute GVHD were not observed. Serological tests for infection with hepatitis A, B and C viruses, varicella-zoster virus (VZV) and herpes simplex virus (HSV) were all negative, and a cytomegalovirus (CMV) antigenemia screen was also negative. All drugs except for CsA and TMP-SMX were withdrawn, because of the possibility of drug-induced liver injury. However, the liver dysfunction did not improve.
On day 25, she underwent an ultrasound-guided liver biopsy (Figure 2 ). Histology revealed lymphocytic infiltrates, intermingled with a few eosinophils and plasma cells, in the portal tracts. Limiting plates were not clearly defined due to cellular infiltrates. There was periductal lymphocytic infiltration and vacuolization of the biliary epithelial cells with exocytosis. In the lobuli, pericentral necrosis was accompanied by lymphocyte infiltration. These histological findings were compatible with the cholangiohepatitic changes of hepatic GVHD. She was treated with prednisolone (1 mg/kg/day), and the AST and ALT levels promptly decreased to 59 IU/l and 147 IU/l, respectively. On tapering the dose of prednisolone, however, her AST and ALT levels started to rise again on day 40. Peak levels of AST and ALT were 265 IU/l and 489 IU/l, respectively by day 61. In contrast, the bilirubin, ALP and ␥-GTP levels were only slightly elevated: the total bilirubin was 1.1 mg/dl, ALP 97 IU/l and ␥-GTP 130 IU/l, respectively. On day 75, she developed cutaneous lesions of chronic GVHD with lichenoid lesions of her oral mucosa. We substituted CsA with FK506 to control GVHD. On day 104, in addition to FK506 0.1 mg/kg/day, she received intravenous methylprednisolone (125 mg/day) for 3 days, followed by oral prednisolone (1 mg/kg/day). Her liver enzyme levels then promptly normalized. The prednisolone was subsequently tapered and terminated by day 350. She has been doing well for more than 19 months after allo-PBSCT.
Discussion
We describe a patient with AML/t-MDS who developed hepatic GVHD presenting as acute hepatitis in the early phase after allo-PBSCT. There are many possible causes for liver disorders in the setting of allogeneic hematopoietic cell transplantation, especially in the early post-transplant phase.
1,2 In our case, the liver aminotransferases were markedly elevated, but the bilirubin, ALP and ␥-GTP levels showed only mild elevation. The differential diagnosis included hepatic veno-occlusive disease (VOD), viral infection, hepatic GVHD and drug toxicity. Preparative regimens for allogeneic hematopoietic stem cell transplantation may induce acute hepatic dysfunction and severe VOD, 6 but clinical manifestations of VOD were absent in our patient. We excluded not only drug-induced liver dysfunction but also acute viral hepatitis due to herpes viruses (HSV, VZV or CMV) and hepatitis A, B and C viruses. Hepatic GVHD is known to occur as cholestatic jaundice with cutaneous and/or intestinal GVHD. The liver is only rarely involved as a sole initial site of GVHD. 1 In typical GVHD, liver function tests reveal a cholestatic picture with increased serum ALP and bilirubin levels. Liver aminotransferases are only mildly elevated. 3 Clinical manifestations of liver dysfunction in our patient were different from that of typical hepatic GVHD; cutaneous lesions and gastrointestinal tract symptoms of acute GVHD were absent and liver aminotransferases were markedly elevated without a cholestatic picture, suggesting acute hepatitis. Therefore, we performed a liver biopsy on day 25 post transplant to make a definitive diagnosis of liver dysfunction. Histological examination showed lymphocyte infiltration of the small bile ducts with epithelial cell collapse, lymphocytic cholangitis and portal lymphoid infiltration. In the reported literature, such histological findings of the liver are characteristic of the cholangiohepatitic lesions of chronic GVHD. 4, 7 Gholson et al 8 reported a case of chronic hepatic GVHD without extrahepatic involvement. In their case, progressive cholestasis developed on day 145 after BMT with reduction of immunosuppressives and responded well to corticosteroid therapy. Strasser et al 9 reported similar cases who developed chronic GVHD of the liver, presenting as acute hepatitis. They described a syndrome of abrupt hepatitic onset of chronic hepatic GVHD in patients receiving mild or no immunosuppression, but their patients developed hepatitis after day 70 post transplant. In our case, the onset of hepatic GVHD was on day 23 post transplant. One of the reasons that this early onset hepatic GVHD presented as acute hepatitis may be related to the hematopoietic stem cell source used in our case. Recently, allo-PBSCT has been used more frequently than allogeneic bone marrow transplantation (allo-BMT). Early reports indicate that allo-PBSCT results in rapid neutrophil and platelet engraftment. One of the major concerns about allo-PBSCT is the possibility of increasing the incidence and severity of GVHD since G-CSF-mobilized PBSC grafts contain one log more T cells and NK cells than does bone marrow grafts. Recent clinical evidence clearly indicates that the incidence and severity of acute GVHD are not significantly different, [10] [11] [12] but the incidence of chronic GVHD in allo-PBSCT is higher when compared to allo-BMT. [13] [14] [15] [16] Further experience is necessary to understand exactly a number of issues concerning differences in GVHD manifestations with allo-PBSCT and allo-BMT, including histology. In our case, the infused PBSC graft contained more than 10-fold lymphocytes, which may have contributed to the early onset of liver injury, presenting a clinical picture of acute hepatitis and chronic hepatic GVHD on histology.
Another possible reason might be modification of clinical material by pre-existing liver dysfunction caused by the earlier treatment and conditioning chemotherapy, which
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In conclusion, we report our clinical experience of early onset hepatic GVHD after allo-PBSCT, which presented as acute hepatitis without a cholestatic picture. The possibility of GVHD should be considered when liver dysfunction suggesting acute hepatitis occurs early after allo-PBSCT.
